ArticleEuropean journal of clinical pharmacology2025
Lowering cyclosporine trough concentration threshold effectively mitigates acute graft-versus-host disease in children with severe β-Thalassemia post hematopoietic stem cell transplantation.
Article in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe relationship between early post-transplantation cyclosporine A (CsA) trough concentrations and the occurrence of acute graft-versus-host disease (aGVHD) was explored in 185 pediatric patients diagnosed with severe β-Thalassemia who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT).
methodsThe time-weighted average (TWA) method was utilized to calculate the average of all CsA trough concentrations taken before aGVHD or within 30 days post-transplantation.
resultsIt was found that TWA CsA trough exposure early post-transplantation was associated with grade II-IV aGVHD and grade III-IV aGVHD in univariate analysis and the Kaplan-Meier curves. After adjusting for potential confounders, multivariate analysis indicated that TWA CsA ≥ 150 µg/L was correlated with a reduced risk of grade II-IV aGVHD (P = 0.003; HR = 0.338; 95%CI, 0.167–0.685) and grade III-IV aGVHD (P = 0.012; HR = 0.203; 95%CI, 0.058–0.708). Notably, the optimal threshold concentration of CsA for preventing the onset of aGVHD in pediatric patients, was found TWA CsA ≥ 131 µg/L was associated with a lower risk of grade II-IV aGVHD (P < 0.001; HR = 0.271; 95%CI, 0.145–0.507, while a TWA CsA ≥ 135 µg/L was correlated with a lower risk of grade III-IV aGVHD (P = 0.002; HR = 0.190; 95%CI, 0.066–0.545). Upon comparing models with different thresholds, no significant improvement in performance was observed for models that incorporated relatively higher thresholds.
conclusionsThis research indicates the initial CsA trough concentration post-transplantation significantly influences the development of aGVHD and children with severe β-Thalassemia undergoing allo-HSCT may not require CsA trough threshold concentrations as high as those required for adults.
Indexed as
Identifiers
41413745What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.